Rolland C. Dickson

Rolland C. Dickson

Auto-generated profile, based on publicly available information

Rolland C. Dickson

Mayo Clinic Arizona

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Journal of Hepatology
Verified
Journal Article
Closed access
BABashar Aqel
Bashar Aqel
KWKarn Wijarnpreecha
Karn Wijarnpreecha
SPSurakit Pungpapong
Surakit Pungpapong
CTC. Burcin Taner
C. Burcin Taner
KRKunam Reddy
Kunam Reddy
RDRolland C. Dickson
Rolland C. Dickson

11 June 2025 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
SKSuaka Kue
Suaka Kue
LBLaura Budvytyte
Laura Budvytyte
MSMariah L. Schroeder
Mariah L. Schroeder
AMAlyssa K. McGary
Alyssa K. McGary
RPRish K. Pai
Rish K. Pai
RDRolland Dickson
Rolland Dickson
Introduction.: Increased steatosis on preimplant liver frozen section is associated with delayed graft function and primary nonfunction. Efforts to standardize histologic assessment have proven difficult. Frozen section artifact and lipopeliosis complicate the detection of steatosis. We aimed to develop and validate an AI model to recognize large droplet fat and fat induced artifact (FIA)/lipopeliosis on preimplantation frozen section and to correlate the AI results with post-transplant clinical parameters. Methods.: The model was applied to 161 consecutive liver transplant specimens with preimplant slides. Results were correlated with traditional and Banff histologic assessment and clinical parameters. Results.: By traditional assessment, steatosis ranged from 0%–40%. The AI model identified a range of 0 to 15.9% steatosis. There was no difference in patient survival by any measures of steatosis. AI steatosis correlated with increased risk of early allograft dysfunction (OR = 1.63, P < .001), respiratory failure (OR = 1.21, P = .003), and more advanced fibrosis (OR = 1.18, P = .030), but was not correlated with graft or patient survival. FIA/lipopeliosis were identified in a range of 0 to 6.42%. In univariate analysis the percentage of FIA/lipopeliosis correlated with both graft and patient survival ( P = .044 and P = .009, respectively), but was not associated with increased risk of early allograft dysfunction, respiratory failure, or advanced fibrosis. Conclusions.: We developed an AI model that quantitates large droplet fat and FIA/lipopeliosis on frozen section slides and found a correlation with post-transplant outcomes. Further studies on larger, multi-institutional cohorts with higher fat containing donors are necessary to determine the role this model may have in organ acceptance decisions.

22 May 2024 in Journal of Liver Transplantation
Verified
Journal Article
Open access
JMJosiah D. McCain
Josiah D. McCain
RDRolland C. Dickson
Rolland C. Dickson
JCJacqueline Cai
Jacqueline Cai
NZNan Zhang
Nan Zhang
SPSurakit Pungpapong
Surakit Pungpapong
DCDavid M.H. Chascsa
David M.H. Chascsa

8 May 2026 in Liver Transplantation
Verified
Journal Article
Closed access
CJChanna R Jayasekera
Channa R Jayasekera
PEPedro Henrique de Borba Engster
Pedro Henrique de Borba Engster
ETEmma C. Terwilliger
Emma C. Terwilliger
SSShirshendu Sinha
Shirshendu Sinha
LLLpc Julie Lankton
Lpc Julie Lankton
RDRolland C. Dickson
Rolland C. Dickson
An abstract is unavailable. This article is available as a PDF only.

12 August 2025 in Liver Transplantation
Verified
Journal Article
Closed access
SESandra Elmasry
Sandra Elmasry
BLBlanca Lizaola-Mayo
Blanca Lizaola-Mayo
NDNathan L. Delafield
Nathan L. Delafield
AMAdam J. Milam
Adam J. Milam
RDRolland C. Dickson
Rolland C. Dickson
DCDavid M.H. Chascsa
David M.H. Chascsa

10 November 2022 in Research Square
Verified
Preprint
Open access
PDF file
MMMatthew Martin
Matthew Martin
SFSherilyn A. Faulkner
Sherilyn A. Faulkner
YSYash Suri
Yash Suri
BABashar Aqel
Bashar Aqel
SPSurakit Pungpapong
Surakit Pungpapong
RDRolland Dickson
Rolland Dickson
Background: Starting in November 2017, 3 liver transplant centers in a single health care system tested and implemented a new protocol to begin accepting livers from hepatitis C virus–seropositive donors for seronegative liver transplant recipients. Although reports show an increase in donors after protocol implementation, there are no details regarding protocol uptake at each transplant center. Literature is limited on protocol implementation that is developed and disseminated by the same protocol producers. The purpose of this study was to evaluate the implementation of a new liver transplant protocol adopted at 3 transplant centers in the same health care system. Methods: A multimethod implementation study using interview, survey, and transplant data was conducted to develop a conceptual model of protocol implementation, identify facilitators of and barriers to implementation, and detect differences in implementation between 3 centers. Results: The conceptual model included 4 domains: rationale, development, implementation, and sustainability. Facilitators included clear, science-based rationale, input from multiple hepatologists, leadership support, and funded pilot data. Barriers included insurance coverage of posttransplant medication and donor field availability. A total of 94 physicians and staff at the 3 transplant centers completed the survey. Implementation factors were all rated moderately high to high at all 3 centers. One-way analysis of variance showed significant differences in mean implementation scores between the centers (F(2, 84)=11.65; P<.001) and between physicians at the 3 centers (F(2, 23)=4.65; P=.02); post hoc comparisons indicated that the scores for physicians differed only between the leading center and 1 participating center. Transplant numbers increased across all 3 centers from 2017 to 2021. Conclusions: Protocol implementation was successful across all 3 centers, especially at the leading transplant center where the protocol was developed. Future efforts should examine the appropriateness of the protocol for other organs (eg, heart, kidney) and additional medical outcome data (eg, mortality, morbidity, quality of life). Trial Registration: Not applicable